Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

Budde, Klemens; Becker, Thomas; Arns, Wolfgang; Sommerer, Claudia; Reinke, Petra; Eisenberger, Ute; Kramer, Stefan; Fischer, Wolfgang; Gschaidmeier, Harald; Pietruck, Frank; ZEUS Study Investigators, (2011). Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet, 377(9768), pp. 837-47. London: Elsevier 10.1016/S0140-6736(10)62318-5

Full text not available from this repository. (Request a copy)

Non-nephrotoxic immunosuppressive strategies that allow reduction of calcineurin-inhibitor exposure without compromising safety or efficacy remain a goal in kidney transplantation. Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strategy for elimination of calcineurin-inhibitor exposure and optimisation of renal-graft function while maintaining efficacy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension

UniBE Contributor:

Eisenberger, Ute

ISSN:

0140-6736

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:25

Last Modified:

17 Mar 2015 21:07

Publisher DOI:

10.1016/S0140-6736(10)62318-5

PubMed ID:

21334736

Web of Science ID:

000288628500031

URI:

https://boris.unibe.ch/id/eprint/8977 (FactScience: 214637)

Actions (login required)

Edit item Edit item
Provide Feedback